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Low-dose intensive insulin therapy in patients with Acute Coronary 
Syndrome accompanied by Left Ventricular Failure: Audit of two UK 
hospitals. 
ABSTRACT (WORD COUNT 296) 
Aims & Objectives:  To determine whether a low-dose intravenous insulin 
regimen reduces blood glucose levels at a timely rate and associated side 
effects among patients with Acute Coronary Syndrome and Left Ventricular 
Failure.  
Background:  Induced hypoglycaemia and the associated risks have 
questioned the benefits of intensive insulin therapy in patients presenting with 
raised blood glucose levels and Acute Coronary Syndromes. Local audit data 
identified that patients with Acute Coronary Syndrome and Left Ventricular 
Failure experienced more hypoglycaemic episodes than those with Acute 
Coronary Syndrome alone.   Consequently, a new regimen of low-dose insulin 
for this group was implemented and audited over 12 months. 
Design:  Audit 
Methods: 36 consecutive patient notes with a diagnosis of Acute Coronary 
Syndrome and blood glucose of ≥10 mmol/L treated with a new insulin therapy 
regimen were analysed.  Data were extracted using a standardised form and 
entered into Excel spreadsheet for analysis. 
Results:  The mean age of the sample was 70 years with 66% of subjects 
being men and 50% presenting with Acute Coronary Syndrome and Left 
Ventricular Failure. The low-dose regimen was effective in achieving 
normoglycaemia, (range 4-8mmol/L) for a consecutive six hour period.  This 
was achieved in 72% of patients and within a median time of 13 hours.   
  2 
Conclusion:  The audit suggests that a low-dose insulin regimen can 
effectively stabilise blood glucose in patients presenting with both Acute 
Coronary Syndrome and Left Ventricular Failure.  The importance of regularly 
monitoring blood sugar levels is vital and highlights the role of nurses in 
minimising patient risk and promoting safety. 
Relevance to practice:  Nurses are instrumental in the safe implementation of 
intensive insulin guidelines.  Close monitoring of patients is essential, enabling 
timely adjustments to treatments and ensuring patient safety.  Regular audits 
allow nurses to evaluate care provision and continue to drive practice forward.  
 
WHAT DOES THIS PAPER CONTRIBUTE TO THE WIDER GLOBAL 
CLINICAL COMMUNITY? 
 Practice audits are a way of increasing nurses awareness of care 
provision and subsequently raising standards  
 Low-dose insulin regimens may be useful for Acute Coronary 
Syndrome (ACS) patients at high risk of hypoglycaemia 
 Reinforces the role of the nurse as pivotal in promoting patient safety 
and minimising risk through their skills in monitoring and making 
timely adjustments to maintain therapeutic goals 
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INTRODUCTION 
Contradictory findings (National Institute for Health and Clinical Excellence 
(NICE) 2013, Ryden et al. 2013) relating to the benefits of intensive insulin 
therapy (an intravenous infusion of insulin and glucose with or without 
potassium)  for individuals presenting with Acute Coronary Syndromes (ACS) 
and hyperglycaemia has resulted in a lack of clear guidance for optimising 
management of these patients.  The European Society of Cardiology (ESC) 
(Ryden et al. 2013) state that patients with diabetes and ACS can benefit from 
an insulin infusion if hyperglycaemia is >10 mmol/L.  In  the United Kingdom 
(UK) The National Institute for health and Clinical Excellence(National Institute 
for Health and Clinical Excellence (NICE) 2013) (NICE) recommend maintaining 
blood glucose below 11.0mmol/L in ACS patients, however advise that intensive 
insulin therapy should only be prescribed where clinically indicated.   
 
This paper discusses how two UK hospitals adapted the delivery of intensive 
insulin therapy in ACS patients at high risk of hypoglycaemia through the 
development and implementation of a new intensive insulin regimen. In 
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BACKGROUND 
Hypoglycaemia is considered a serious side effect of intensive insulin therapy 
with evidence linking hypoglycaemia to adverse outcomes in ACS patients.  
One study involving 713 patients with ACS and diabetes managed with a range 
of treatments (including IV insulin) reported that a hypoglycaemic episode 
(<3.0mmol/L) during admission was an independent predictor of death within 
two  years (HR 1.93, 95% confidence interval, 1.18 - 3.17) (Svensson et al. 
2005).   A retrospective cohort study of 7820 patients presenting with acute 
Myocardial Infarction (MI) and hyperglycaemia (Kosiborod et al. 2009a) aimed 
to further explore the link between hypoglycaemia and mortality.  The results 
however indicated that hypoglycaemia was only a predictor of increased 
mortality in patients not treated with insulin (OR 2.32 95% confidence interval, 
1.31 – 4.12).  The authors concluded that an increased mortality risk is confined 
to patients developing hypoglycaemia spontaneously and not as a result of 
insulin therapy.  The publication of conflicting evidence has however questioned 
the clinical value of intensive insulin therapy in the management of ACS 
patients presenting with hyperglycaemia.   
 
Local concerns regarding the frequency of hypoglycaemic episodes among 
ACS patients following initiation of treatment led to a review of the current 
practice.  A preliminary audit of case notes identified that hypoglycaemic 
episodes affected 13 individuals out of 130.  Following further data analysis it 
appeared that five of the hypoglycaemic episodes occurred in patients 
presenting with both ACS and Left Ventricular Failure (LVF).  There is some 
evidence to suggest that patients with LVF may be at higher risk of 
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hypoglycaemia (Kosiborod et al. 2009a, Mellbin et al. 2009), it was therefore 
postulated that these patients may benefit from a lower insulin infusion rate to 
reduce the frequency of iatrogenic hypoglycaemia.   
 
Drawing on initial audit findings and in line with the ESC guidelines (Ryden et al. 
2013), a redesigned regimen was developed collaboratively by the cardiology 
and diabetes health specialists.  The revised guideline recommended initiation 
of intravenous intensive insulin therapy in patients admitted with ACS and with 
blood glucose levels of ≥10 mmol/L.  Based on the presence or absence of LVF 
(figure 1) clinical staff were directed to an appropriate bespoke insulin regimen.  
Those with ACS were prescribed the standard insulin regimen, those presenting 
with ACS and LVF were treated with the low-dose insulin regimen.  Both 
regimens utilised an insulin dilution of one unit Actrapid insulin per 1ml of 
normal saline (0.9%) and required hourly capillary blood glucose (CBG) 
monitoring.  The only difference between the regimens was the hourly infusion 
rate, with the low-dose regimen delivering half the standard regimen rate 
(Figure 2).  The aim of this approach was to reduce treatment induced 
hypoglycaemia specifically in hospitalised patients presenting with ACS and 
ACS in conjunction with LVF. 
 
INSERT FIGURE 1 & 2 
 
The revised intensive insulin therapy for ACS guideline (Figure 2) was 
implemented in clinical practice in December 2012 and was accompanied by a 
comprehensive teaching programme aimed at medical and nursing staff across 
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all shifts.  Implementation strategy is important to the success of any clinical 
guideline or protocol (Middleton 2012) as simply providing a new protocol or 
guideline is unlikely to result in a change in practice (Knowles et al. 2014). The 
local teaching programme content included the rationale behind the guideline 
change, risks of hypoglycaemia in ACS patients, current European guidelines, 
determining patient eligibility, guidance on initiating the new regimen and patient 
monitoring.  Posters and evidence based learning resources were made 
available to staff including contact details for further support. In the weeks 
following, a team of cardiac and diabetes nurses visited wards where ACS 
patients would be admitted to ensure understanding and commitment to the 
revised regimen and answer any questions or aspects of concern 
 
In order to assess the impact of the new guideline a follow-up audit was 
performed 12 months after implementation.  This paper, therefore aims to report 
on the results of this follow up audit to determine whether the revised intensive 
insulin regimen led to more stable CBG levels and reduced rates of 
hypoglycaemic episodes in ACS patients presenting with and without LVF as 




The study was a re-audit of practice following implementation of the revised 
intensive insulin regimen for ACS patients.  Audit is a cyclical process and 
enables nurses and other health professionals to continuously seek to improve 
patient care (Patel 2010).  Considerable effort is required to initiate changes in 
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practice and it is imperative to measure the success of implementing any new 
guideline or protocol (Higuchi et al. 2011).   Audit is an effective way to do this, 
however in order to be successful audit must be carefully organised and 
meaningful to both those who conduct it and those who receive the results 
(Patel 2010).  It is vital that nurses administering the care and using the revised 
guideline are engaged in the process as successful audit has been noted to 
improve communication between professional groups, professional satisfaction 
and knowledge (Johnston et al. 2000).  
 
Sample 
The Myocardial Ischaemia National Audit Project (MINAP) database was used 
to identify eligible patients.  MINAP is a multi-centre prospective registry held by 
the National Institute for Cardiovascular Outcomes Research (NICOR).  All UK 
hospitals are required to submit MINAP data on patients admitted with ACS, 
with each entry providing comprehensive details of the patient journey (Alabas 
et al. 2014).  Within the two study hospitals, the cardiology teams are 
responsible for the accuracy of clinical data entered for each case.  The MINAP 
database was therefore considered the most accurate source of obtaining the 
sample for this audit.   
 
During the audit period (December 2012- December 2013), 619 patient 
episodes were entered in the local MINAP database.  Of these, 137 had 
admission blood glucose levels of ≥10 mmol/L, the criteria for intensive insulin 
therapy regimen eligibility.  Intensive insulin therapy was indicated in 47 of the 
137 episodes. Of the 47 medical notes, six were unavailable, and five patients 
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were excluded from analysis as alternative intensive insulin therapy regimens 
were prescribed.  In total 36 notes were analysed for audit purposes. The final 
sample included ACS patients both with and without LVF treated with the 
standard regimen and with the revised low-dose intensive insulin therapy 
regimen. 
 
Data collection  
Data was extracted from the medical notes by two cardiology audit nurses using 
a standardised form.  The form was designed by MINAP for use in the Trial of 
Insulin Therapy to Achieve Normoglycaemia in ACS (TITAN-ACS) study 
(Myocardial Ischaemia National Audit Project (MINAP) 2010) and had been 
used in the original audit to ensure comparability of results, therefore it was not 
piloted in this follow-up audit.  Data collection included demographic variables, 
diabetic history, clinical diagnosis, the type of insulin regimen administered; 
length of time intensive insulin therapy was prescribed for; CBG levels 
measures at different time points and recorded episodes of hypoglycaemia. 
Additional fields specific to the local guideline were added to widen the scope of 
the audit, examples included; any documented changes to the prescribed 
regimen, correct prescription of the regimen and the presence of nurses 
signatures on monitoring records.  Normoglycaemia was defined as CBG within 
range 4-8mmol/L and maintained for a six hour period.  All CBG measurements 
were performed by trained staff using the Abbot Optium Exceed glucose meter, 
which was calibrated daily. A hypoglycaemic episode was defined as a CBG 
level of ≤3 mmol/L.  
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Data Analysis 
The data was manually entered into an Excel (2010) spreadsheet and 
descriptive statistical analysis included median and mean scores. Analysis of 
demographics included gender, age, ethnicity, previous medical history and 
diabetic status on admission.  Response to the regimen was assessed by 
median times to achieve normoglycaemia as defined above and mean CBG 
levels during the first 24 hours following initiation of insulin therapy.   Mean 
values have been reported partly to facilitate comparisons with other published 
studies in the field (Cheung et al. 2006, Goldberg et al. 2004, Kosiborod et al. 
2009b).  Additionally if median CBG levels over the initial 24 hour period are 
plotted there is an equal symmetrical pattern as for mean values, therefore the 
use of the latter has been applied.  Patient monitoring, adjustments to 




Table 1 provides demographics of the re-audit study sample (n=36). The low-
dose insulin regimen group (Group A) comprised of 18 patients, with a mean 
age of 72 years and of these eight were women.  The remaining 18 subjects 
(Group B) received the standard insulin regimen, had a mean age of 68 years 
and of these four were women. Those in Group A had higher CBG levels on 
admission (18.5 mmol/L vs. 15.6 mmol/L), a history of previous Myocardial 
Infarction (MI) (39% vs. 17%) and heart failure (28% vs. 17%) when compared 
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to patients in Group B.  At the initiation of their respective intensive insulin 
regimens, mean CBG levels were similar, as seen in table 1. 
 
INSERT TABLE 1 
 
Response to regimen  
Both groups achieved target CBG levels of 4-8 mmol/L which were maintained 
for a six hour period,  73% in  Group A achieved this and 71% in  Group B.  The 
median length of time to achieve first CBG within the target range for both 
groups was six hours however, median time for Group A was 7.8 hours and 4.5 
hours for Group B.  The median time to complete a consecutive six hour 
normoglycaemic period was 13 hours in both groups.   Figure 3 shows the 
response in CBG levels for the first 24 hours following initiation of insulin 
therapy.  The figure illustrates an overall downward trend of CBG levels, 
although at 17 hours following initiation of the insulin therapy, group A patients 
experienced a spike in their CBG levels.  
 
INSERT FIGURE 3 
 
Incidence of hypoglycaemic episodes 
In the re-audit three (out of 36) patients experienced insulin induced 
hypoglycaemia (CBG≤ 3 mmol/L).  Of these, two had been diagnosed with ACS 
and LVF and were prescribed the low-dose regimen. In both these patients, 
presenting CBG levels were >20 mmol/L and hypoglycaemic episodes occurred 
>24 hours after the infusion had commenced. 
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Patient monitoring and regimen adjustments  
The frequency of CBG monitoring was recommended to be hourly although in 
practice this occurred 1-2 hourly.  In total 22% of patients (n=8) required 
adjustment to their insulin regimens.  In Group A, four patients required an 
increase from the low dose to standard regimen due to poor glycaemic control.  
Through ongoing monitoring of patients by nurses, four in group B required 
conversion to the low dose regimen, in two instances this was due to 
persistently low CBG levels on the standard regimen and in the other two cases 
this was because they developed LVF.   
 
DISCUSSION 
This audit of practice reports on the introduction of a low-dose intensive insulin 
therapy regimen aimed at providing better glycaemic control for patients 
admitted with ACS with or without LVF. The discussion is structured around four 
key areas highlighting the implications for practice and the role of coronary care 
nurses in managing the safety of patients receiving insulin therapy. 
 
Baseline Characteristics  
As table 1 highlights Group A patients had a higher incidence of previous MI 
and heart failure, they also presented with LVF and as a result received the low-
dose regimen.  Consequently, it is reasonable to suggest that they were at more 
risk of complications from receiving intensive insulin therapy. It has been 
reported that the severity of illness can increase the likelihood of hypoglycaemic 
episodes (Nasraway 2007).  Kosiborod et al’s (2009a) research identified that 
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patients experiencing hypoglycaemia were older with multiple co-morbidities.   
This was further substantiated by a study of 1253 ACS patients treated for 
hyperglycaemia which reported that patients experiencing hypoglycaemia were 
those with a more serious prognosis.  These patients were older, with low body 
weight and often had a history of heart failure (Mellbin et al. 2009).   The 
authors postulate that hypoglycaemia could in fact be a marker of critical illness 
rather than a direct cause of adverse events.  Recognising patients with a high 
severity of illness and therefore at higher risk of hypoglycaemia is therefore vital 
(Nasraway 2007). It has been suggested that a more careful approach to 
glucose management in order to avoid hypoglycaemia may in fact result in 
greater patient benefit (Nasraway 2007, Whitehorn 2007, Kosiborod et al. 
2009a, Kosiborod et al. 2009b, Mellbin et al. 2009).  The use of a low-dose 
insulin regimen in patients presenting with ACS accompanied by LVF is 
potentially one solution for  enabling  CBG levels to be managed in a more 
controlled manner, however further research would be essential to validate the 
observations in this paper. 
 
Response to regimen 
The aim of intensive insulin therapy is to return a patient’s blood glucose level 
within a normal range in a safe and timely manner as this is associated with 
positive outcomes (Aragon 2006). However, if unmonitored, hypoglycaemia, a 
serious side effect of intensive insulin therapy can develop questioning the 
safety of its use (Goldberg et al. 2004, Mellbin et al. 2009, Alabas et al. 2014).  
In previous studies a median length of time to achieving the therapeutic target 
range in patients with ACS of between three to four hours has been reported 
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(Cheung et al. 2006, Kosiborod et al. 2009b).  In these studies however, 
patients CBG levels prior to insulin administration ranged between 10.8mmol/L 
and 12.8mmol/L. In this audit, patients presented with an average baseline CBG 
of 17 mmol/L (SD 6.8), (see table 1) and this may account for the difference in 
time to resolution of normal values.  Goldberg et al (2004) using an insulin 
infusion protocol with a sample of medical intensive care patients (n=52) 
reported mean CBG levels of 16.6mmol/L at insulin initiation and median time to 
achieving the first target measurement of nine hours.  While Goldberg et al’s 
(2004) population comprised of patients admitted to a medical Intensive Care 
Unit, the combined results with this audit infer that a relationship may exist 
between CBG level at insulin initiation and time to achieving target CBG values. 
 
When assessing maintenance of target ranges, differing reporting methods 
make comparing data problematic.  In this audit, successful blood glucose 
normalisation was defined as the maintenance of  CBG levels within the 
prescribed target range for a consecutive six hour period in line with the TITAN-
ACS study (Myocardial Ischaemia National Audit Project (MINAP) 2010).  The 
sustained six hour period was completed within a median time of 13 hours in 
both groups.  This seems to indicate that despite Group A patients receiving 
lower doses of insulin, CBG levels continue to normalise at similar rates as 
those receiving the standard regime.   
 
A rise in CBG measurements at 17 hours from initiation of insulin (see Figure 3) 
for  group A patients merits explanation. Reviewing nursing and medical patient 
notes the rise in CBG at 17 hours coincides with a meal time.  The short-lived 
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spike in CBG can  therefore be attributed the effects of nutritional intake.  
Sliding scale insulin regimes have been criticised for their inability to 
individualise insulin demands in relation to types and amounts of food to be 
consumed, with insulin doses often based on pre-meal CBG levels (Coggins 
2012).  This indicates that perhaps patients on the low-dose regimen need 
closer monitoring by nurses around meal times to ensure stable CBG levels.   
 
Incidence of Hypoglycaemic episodes 
Hypoglycaemia remains a serious risk and adverse event associated with the 
initiation of intensive insulin therapy often resulting in a low treatment threshold 
of patients presenting with ACS and hyperglycaemia (Kosiborod et al. 2009a).  
If a regimen can be shown to reduce the incidence and risk of hypoglycaemic 
episodes whilst still normalising glucose levels this could have a dramatic effect 
on preventing adverse events for ACS patients and improving recovery.   
 
Direct comparison of hypoglycaemic rates with other studies is problematic due 
to definition differences, however some comparisons can be inferred.  The 
Diabetes mellitus, Insulin Glucose infusion in Acute Myocardial Infarction 
studies (DIGAMI I and II) both define hypoglycaemia as a CBG <3mmol/L and 
report incidence rates of between 15% (Malmberg et al. 1995) and 12% 
(Malmberg et al. 2005).  However, the HI-5 study (Cheung et al. 2006) reported 
a 10% incidence of hypoglycaemia with a slightly higher CBG threshold 
(<3.5mmol/L).     
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A study by Avanzini et al (Avanzini et al. 2009) implemented an intensive insulin 
therapy nomogram in which calculations accounted for both current CBG value 
and the percentage change from the previous level,  enabling stricter and safer 
glycaemic control  in ACS patients. It was reported that this nurse led intensive 
insulin therapy protocol was well received, with hypoglycaemia (CBG <4 
mmol/L) occurring in 17 out of 91 patients (18.7%). When compared to these 
studies, the revised regimen presented in this audit was associated with   a 
lower rate of hypoglycaemic episodes (8%), however caution is required in 
relation to the data due to our sample size and selection of patients 
 
It is important to recognise that any treatment for hyperglycaemia carries a risk 
of inducing hypoglycaemia, particularly in patients who are acutely unwell 
(Kosiborod et al. 2009a).  The implementation of the new regime resulted in a 
2% decrease in hypoglycaemic episodes. While this is not a substantial 
reduction, without empirical evidence it is difficult to establish whether further 
progress can be made in this area.   
 
Nursing responsibilities 
Our data confirms that hypoglycaemic episodes occurred in the low-dose 
intensive insulin regimen, however these were the result of protocol violation 
and avoidable through more consistent CBG monitoring.  Nurses  play a vital 
role in ensuring the safe implementation of intensive insulin therapy, and in 
monitoring the wellbeing of their patients by identifying changes in clinical status 
and responding appropriately according to evidence base guidelines (Monteiro 
et al. 2009).  Nurse workloads continue to increase which can reduce the quality 
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of care provided and lead to uncompleted tasks (Hinno et al. 2012).  Regular 
CBG monitoring alongside the calculation and titration of insulin infusion rates 
further increases the workload and burden on nursing staff (Sauer & Van Horn 
2009).  A  survey  of 66 intensive care nurses identified that the majority 
understood the importance of glycaemic control but felt that achieving hourly 
monitoring to optimise blood glucose was labour intensive and costly (Aragon 
2006).  It is vital that nurses recognise the importance of their role in managing 
patients prescribed intensive insulin therapy as a decrease in vigilance can put 
patients as risk of prolonged hypoglycaemia (Whitehorn 2007).  This was 
demonstrated in a study comparing four Intensive Care Units (ICU) using the 
same intensive insulin protocol.  Results showed that the ICU measuring CBG 
most frequently achieved both the lowest mean blood glucose and the lowest 
hypoglycaemia rate (Nasraway 2007). This reinforces the importance of nurses 
regularly monitoring CBG to enable timely and appropriate clinical interventions 
to be applied before hypoglycaemia occurs. It is through these actions that 
nurses contribute to quality of care and to minimising avoidable risks.  In the 
Avanzini et al study (2009) nurses identified that although the guideline added 
to their workload, safety and efficacy results increased their motivation and 
reinforced the importance of monitoring.  It is therefore vital for areas to 
regularly audit compliance with intensive insulin therapy regimens and provide 
feedback to frontline nursing staff administering the care. Through this 
continuous monitoring and feedback cycle, nurses can remain confident in 
providing quality care and patient safety can be ensured. 
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Limitations 
While the sample size of this audit was small and precludes wide 
recommendations, it has produced some important results.  Further research 
arguably is required to determine the value and efficacy of various insulin 
regimens for patients with ACS and LVF, who present with a CBG of 
>10mmol/L. This should include multi-centre randomised control trials 
comparing low-dose insulin regimens against standard regimens in this group of 
patients.   As the majority of patients included in this audit were Caucasian, it 
would be important to ensure other ethnic backgrounds are represented and 
that the selection of individuals for inclusion is more rigorous to systematically 
evaluate the role of low-dose insulin regimes. Additionally, use of standardised 
measures for hypoglycaemia would be helpful too. 
 
The regimen was implemented across two hospitals, with the reduction in 
reported hypoglycaemia not analysed for statistical significance, therefore care 
must be taken when applying the findings to the wider population of ACS 
patients presenting with hyperglycaemia. 
 
CONCLUSION 
When managing hyperglycaemia in ACS patients numerous strategies are 
available and the debate as to which is best will continue until definitive trial 
data becomes available.  In the meantime it is left to individual centres to 
implement protocols and guidelines that they feel are in the best interest of their 
patients.  Clinical audit is crucial in this process allowing centres to continually 
evaluate and develop their practice to improve the standards and safety of 
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patient care. Indeed, this audit of practice has demonstrated that a low-dose 
insulin regimen for patients with ACS and LVF who present with a blood sugar 
of >10mmol/L can safely assist the control of blood sugar levels and minimise 
unwanted risk.  However, it is vital that nurses monitor patients closely to enable 




RELEVANCE TO PRACTICE 
The informed application of guidelines is pivotal in promoting excellence in care 
delivery, promoting patient safety and minimising risk. Nurses because of their 
clinical expertise and proximity to the patient are instrumental in promoting 
standards and ensuring that patients do not suffer harm. Using audit data from 
that continually evaluating care provision is powerful in promoting change and 
assisting in embedding clinical innovation. 
Word count 3576  
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ACS patient presenting 
with blood glucose 
≥10mmol/litre 
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INSULIN INFUSION: adjust according to sliding scale below 
ALWAYS ENSURE GLUCOSE IS RUNNING WHILE INSULIN INFUSION IS IN PROGRESS 
ACTRAPID 50 units in 50mls of Sodium Chloride 0.9% (i.e. 1 unit/ml) 
 Alternative scales may be needed for patients with high insulin requirements. For patients on > 50 units insulin/ day 
or if capillary blood glucose remains >15mmol for >2 hours use the alternative scale with double the recommended 
insulin doses (see table below).   
 Low dose sliding scale should be used for patients following LVF regimen and/or long-acting insulin analogue 
continued 
 Consider low dose sliding scale insulin in elderly and those on sulphonylureas prior to admission 
 
Usual daily 















>75 units  















< 4 mmol/L Treat hypoglycaemia according to NBT guidelines 
0.5 0.0 1 1  
4.0-5.9 1 0.5 2 3  
6.0-8.9 2 1.0 4 5  
9.0-10.9 3 1.5 6 7  
11.0-12.9 4 2.0 8 10  
13.0 – 14.9 5 2.5 10 12  









Doctors signature      
Date and time      
 
*Please note: Columns four and five apply only to patients using high doses of insulin as part of their daily regimen.  
These patients usually require a higher sliding scale rate during an acute episode in order to normalise Capillary Blood 
Glucose levels.  
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  n= 36 (100%) n=18 (50%) n= 18(50%) 
Male 24 (67%) 10 (56%) 14 (78%) 
Female 12 (33%) 8 (44%) 4 (22%) 
White 26 (72%) 13 (72%) 13 (72%) 
Black 0 0 0 
Asian 0 0 0 
Ethnicity not stated 10 (28%) 5 (28%) 5 (28%) 
Previous Myocardial Infarction 10 (28%) 7 (39%) 3 (17%) 
Previous history of Heart Failure 8 (22%) 5 (28%) 3 (17%) 
Mean Age (years) (SD) 70 (10.7) 72 (10.7) 68 (10.6) 
Median Age (years) 70 71 70 
Mean baseline admission CBG  (SD) 17 mmol/L  
(6.8) 
18.5  mmol/L 
(7.6) 
15.6  mmol/L 
(5.7) 
Median admission CBG  15.3 mmol/L 16.8 mmol/L 14.0 mmol/L 







Median CBG on commencement of infusion  12.5 mmol/L 12.3 mmol/L 12.8 mmol/L 
Legend: ACS: Acute Coronary Syndrome LVF: Left Ventricular Failure  
SD: Standard deviation  CBG: Capillary Blood glucose 
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